Ms. Lu's tumor has metastasized extensively to the peritoneum and lymph nodes, making it difficult to completely remove the lesion through direct surgery. At this point, neoadjuvant chemotherapy played a crucial role :

*. The primary lesion was reduced

by two cycles of chemotherapy. Ms. Lu's tumor marker CA125 decreased from 822.3U/ml to 29.5U/ml, and imaging revealed that the metastatic lymph node volume had shrunk from 2.2*1.4cmto 0.7*0.5cm. Reducethe adhesionbetween tumor and normal tissues, and improve the complete tumor resection rate.

Assess the sensitivity to chemotherapy drugs

Based on the tumor's response to neoadjuvant chemotherapy, the sensitivity of the patient tochemotherapy drugscan be assessed, facilitating the reasonable formulation of subsequent chemotherapy regimens.

* Improving survival prognosis

Some studies have shown that the CR (complete remission) rate of ovarian cancer patients undergoing neoadjuvant chemotherapy combined with surgeryreaches14.89%, while the CR rate for patients undergoing surgery aloneis only4.54%. Compared to surgery alone, neoadjuvant chemotherapy followed by surgery can effectively control the patient's condition and significantly improve the short-term efficacy for advanced ovarian cancer      

       

* Radical surgery for ovarian cancer

with resection of pelvic lesions and complete removal of the uterus, bilateral adnexa, greater omentum, and involved lymph nodes;

* Lymph node dissection range

Pelvic and para-aortic lymph nodes were dissected and removed ;

* Postoperative chemotherapy intensification

to further eliminate residual cancer cells .

Surgery, radiotherapy, and chemotherapy are the "three axes" of tumor treatment, but so far, no single method can completely eliminate cancer cells in the body. Especially for early-stage tumor patients, many undergo initial surgery where the tumor is completely removed, and imaging tests also show no signs of cancer. However, in reality, some cancer cells may have already spread to other parts of the body through the lymphatic or blood systems. Meanwhile, chemotherapy and radiotherapy can reduce patients' immunity to some extent, thereby increasing the risk of tumor recurrence and metastasis.

Therefore, consolidation therapy after surgery is very important. After completing conventional treatment, Ms. Lu chose to receive vNKT cell therapy. Eliminate intrinsic micro-residual and dormant cancer cells, while reconstructing the immune surveillance system, effectively reducing the risk of tumor recurrence and simultaneously enhancing the probability of clinical cure.

     

Imaging examination:

In November 2022, PET-CT and MR imaging revealed an irregular cystic and solid mass in the right parauterine region with increased FDG metabolism, suggesting malignancy. In April 2023, a follow-up examination showed no signs of the mass, but a small amount of fluid accumulation in the pelvic cavity was observed. Considering the patient's medical history, it was considered to be a postoperative change. In September 2023, a follow-up examination was performed to assess the postoperative changes of the irregular cystic and solid mass in the right parauterine region. In March 2024, a follow-up examination revealed a small amount of fluid accumulation in the pelvic cavity, and the patient was scheduled for follow-up. On September 12, 2024, a follow-up examination was conducted to assess the postoperative changes of the irregular cystic and solid mass in the right parauterine region.

     

Long-term survival of cancer patients cannot be achieved solely through a certain treatment method, but rather through systematic treatment encompassingprecise diagnosis, standardized treatment, and postoperative rehabilitation. Ms. Luwas diagnosed with stageIV ovarian cancer, with distant metastasis at the time of diagnosis. Her postoperative2-year relapse-free period is not accidental. Ms. Lu's treatment experience tells us that

: Traditional chemoradiotherapy, akin to carpet bombing, may rapidly destroy visible tumors but also disrupts the body's immune microenvironment, which serves as a breeding ground for relapse and metastasis. While vNKT cell therapy can eliminate residual cancer cells, it can also reshape the immune microenvironment , fundamentally preventing recurrence and metastasis.